section name header

Pronunciation ⬇

koe-less-TEAR-a-meen

Classifications ⬆ ⬇

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: bile acid sequestrants

Indications ⬆ ⬇

REMS


Unlabeled Use:
  • Diarrhea associated with excess bile acids.

Action ⬆ ⬇

  • Bind bile acids in the GI tract, forming an insoluble complex. Result is increased clearance of cholesterol.
Therapeutic effects:
  • Decreased plasma cholesterol and low-density lipoprotein (LDL) cholesterol.
  • Decreased pruritus.

Pharmacokinetics ⬆ ⬇

Absorption: Action takes place in the GI tract. No absorption occurs.

Distribution: No distribution.

Metabolism/Excretion: After binding bile acids, insoluble complex is eliminated in the feces.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(hypocholesterolemic effects)

ROUTEONSETPEAKDURATION
PO24–48 hr1–3 wk2–4 wk

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: irritation, rashes

EENT: irritation of the tongue

F and E: hyperchloremic acidosis

GI: abdominal discomfort, constipation, nausea, fecal impaction, flatulence, hemorrhoids, perianal irritation, steatorrhea, vomiting

Metab: vitamin A, D, and K deficiency

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Prevalite, Questran, Questran Light

Canadian Brand Names ⬆ ⬇

Olestyr, Olestyr Light

Code ⬆

NDC Code